Article Text

Download PDFPDF
Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register

Footnotes

  • * A complete list of centres and investigators can be found in Cambou JP et al Arch Mal Coeur Vaiss 2007;100:524-534.

  • Funding The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted educational grants from Pfizer and Servier. Additional support was obtained from a research grant from the French Health Insurance system (Caisse Nationale d'Assurance Maladie).

  • Competing interests Dr Danchin has received fees for participating in symposia organised by, or served as a temporary consultant for Astra-Zeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis, all of whom manufacture statins, and has been involved in a number of studies sponsored by these companies.

    Laurent Fauchier has received fees for participating in symposia organised by Astra-Zeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Sanofi-Aventis, all of whom manufacture statins, and has been involved in a number of studies sponsored by these companies.

    Eloi Marijon: None.

    Claude Barnay: None.

    Alain Furber has received fees for participating in symposia organised by Lilly, Sanofi-Aventis, Servier, and has been involved in a number of studies sponsored by these companies.

    Philippe Mabo: None.

    Paul Bernard: None.

    Jean-Jacques Blanc: None.

    Xavier Jouven: None.

    Jean-Yves Le Heuzey has received fees for participating in symposia organised by, or served as a temporary consultant for Sanofi-Aventis, Meda, Boehringer Ingelheim, Servier and Medtronic, and has been involved in a number of studies sponsored by these companies.

    Bernard Charbonnier: None.

    Jean Ferrières has obtained grants from Astra Zeneca, Boehringer Ingelheim, Pfizer and Sanofi-Aventis.

    Tabassome Simon reports receiving consulting fees from Bayer-Schering, Pfizer and Eli Lilly, Sanofi-Synthelabo; lecture fees from Bayer-Schering; and grant support from Pfizer and Servier.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • * A complete list of centres and investigators can be found in Cambou JP et al Arch Mal Coeur Vaiss 2007;100:524-534.

  • Funding The FAST-MI registry is a registry of the French Society of Cardiology, supported by unrestricted educational grants from Pfizer and Servier. Additional support was obtained from a research grant from the French Health Insurance system (Caisse Nationale d'Assurance Maladie).

  • Competing interests Dr Danchin has received fees for participating in symposia organised by, or served as a temporary consultant for Astra-Zeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis, all of whom manufacture statins, and has been involved in a number of studies sponsored by these companies.

    Laurent Fauchier has received fees for participating in symposia organised by Astra-Zeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Sanofi-Aventis, all of whom manufacture statins, and has been involved in a number of studies sponsored by these companies.

    Eloi Marijon: None.

    Claude Barnay: None.

    Alain Furber has received fees for participating in symposia organised by Lilly, Sanofi-Aventis, Servier, and has been involved in a number of studies sponsored by these companies.

    Philippe Mabo: None.

    Paul Bernard: None.

    Jean-Jacques Blanc: None.

    Xavier Jouven: None.

    Jean-Yves Le Heuzey has received fees for participating in symposia organised by, or served as a temporary consultant for Sanofi-Aventis, Meda, Boehringer Ingelheim, Servier and Medtronic, and has been involved in a number of studies sponsored by these companies.

    Bernard Charbonnier: None.

    Jean Ferrières has obtained grants from Astra Zeneca, Boehringer Ingelheim, Pfizer and Sanofi-Aventis.

    Tabassome Simon reports receiving consulting fees from Bayer-Schering, Pfizer and Eli Lilly, Sanofi-Synthelabo; lecture fees from Bayer-Schering; and grant support from Pfizer and Servier.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.